The TASQ project aims to develop an orally active substance for the treatment of prostate cancer. Active Biotech is cooperating in the project with Professor John T. Isaacs at Johns Hopkins University, Baltimore, USA. Angiogenesis plays a seemingly pivotal role in the growth and progression of prostate cancer. ABR-215050 restricts the blood supply to deposits of solid tumors. This antiangiogenic ability is not via VEGF receptor kinase inhibition. ABR-215050 has been found to inhibit the growth of several human prostate carcinomas grown subcutaneously and orthotopically in mice and rats. Hence, the use of ABR-215050 to halt or retard the progression of prostate cancer would be sensible.

Active Biotech has successfully performed an initial Phase I clinical trial of the TASQ candidate drug. The trial was performed in healthy volunteers in co- operation with the University Hospital in Lund. The aim of the study was to find the pharmacokinetic characteristics of the candidate drug in humans. The study shows that the candidate drug TASQ has pharmacokinetic properties that make it well suitable for oral administration. The following dose escalation study in healthy volunteers showed that TASQ was tolerated at dose-levels expected to be effective in prostate patients. A Phase II study in patients with prostate cancer is ongoing.

Europe - Status Granted - Year of expiry 2019

The Us - Status Granted - Year of expiry 2019

Japan - Status Pending - Year of expiry 2019

"User area"

Europe - Pending - Year of expiry 2020,

The Us - Granted- Year of expiry 2020,

Japan - Pending - Year of expiry 2020.

Active Biotech seeks a strategic partner in this early phase of the project to ensure timely development of the compound. Terms of the collaboration are flexibel and to be discussed